Publication date: Apr 11, 2019
This post was originally published on this site Tecfidera (dimethyl fumarate) is more efficient at preventing relapses, and has a lower discontinuation rate than Aubagio (teriflunomide), according to a Danish study. In order to make a direct comparison between the two therapies, researchers analyzed patients with RRMS registered in the Danish Multiple Sclerosis Registry who took Aubagio or Tecfidera from October 2013 to May 2018. Tecfidera was more effective at reducing ARRs, with patients showing an adjusted 42% lower relapse rate compared to Aubagio. Treatment discontinuation due to disease worsening was higher in patients treated with Aubagio (22. 1%) compared to Tecfidera (10. 2%), reflecting the higher relapse activity seen in the Aubagio group. The team concluded that -for patients with RRMS, DMF [Tecfidera] is more effective in preventing relapses. ..compared with TFL [Aubagio]. “
|disease||DOID||relapsing-remitting multiple sclerosis|
|disease||MESH||relapsing-remitting multiple sclerosis|
|drug||DRUGBANK||Antithymocyte immunoglobulin (rabbit)|
- Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
- Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
- Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.